You are here: Industry Insights > J&J

News List

Are J&J, Endo and Allergan in line for 'global' opioid settlements? fiercepharma
September 02, 2019
With thousands of opioid lawsuits piling up in a Cleveland courthouse, drugmakers and plaintiffs seemed at an impasse on how to move forward.
J&J ordered to pay $572m to Oklahoma over opioid crisis europeanpharmaceuticalreview
August 29, 2019
The pharmaceutical company is planning to appeal the decision to pay the state for damages relating to the US opioid crisis.
FTC investigates contracts regarding autoimmune disease drug, Remicade europeanpharmaceuticalreview
August 02, 2019
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
J&J launches research consortium for new drugs against TB pharmaceutical-technology
July 25, 2019
Johnson & Johnson (J&J) has formed an international research consortium to focus on the discovery and development of new antibiotics to treat tuberculosis (TB).
Oklahoma seeks $17bn from J&J for opioid crisis pharmaceutical-technology
July 17, 2019
Lawyers for the US state of Oklahoma have argued that Johnson & Johnson (J&J) should be held responsible for driving opioid epidemic in the country and pay around $17bn over 30 years to address the crisis.
J&J announces PPP for Investigational Prophylactic HIV Vaccine biospectrumasia
July 16, 2019
Janssen’s mosaic vaccine is designed as a global vaccine with the goal of preventing infections from the wide range of viral strains responsible for the HIV pandemic
J&J's Darzalex pads blockbuster sales with another myeloma nod in new patients fiercepharma
July 04, 2019
Johnson & Johnson multiple myeloma drug Darzalex hasn’t stopped rolling since hitting the market. After picking up its first nod in previously untreated patients last May, the drug added a second indication in new patients on Thursday—and its sixth overal
J&J depression drug Spravato gets half-hearted backing from VA doctors despite Trump's zeal fiercepharma
June 28, 2019
Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the U.S. Department of Veterans Affairs. Agency clinicians instead approved the depression spray’s use on a limited basis, requiring patie
How to correct opioid misinformation? Spend $285M on counter-marketing, expert says in J&J trial fiercepharma
June 12, 2019
Countless lawsuits have sought to estimate the costs of fixing the U.S. opioid and addiction epidemic. Now, thanks to an expert in Oklahoma's ongoing trial against Johnson & Johnson, we have one dollar figure.
J&J announce first-of-its-kind portopulmonary hypertension study results pharmatimes
June 11, 2019
Johnson & Johnson's Opsumit (macitentan) has shown significant improvement in pulmonary vascular resistance (PVR) in patients with portopulmonary hypertension (PoPH) after 24 weeks, in data published in The Lancet Respiratory Medicine.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page